Construction and application of the criteria for drug utilization evaluation of low-dose rivaroxaban in atherosclerotic cardiovascular disease
- VernacularTitle:小剂量利伐沙班用于动脉粥样硬化性心血管疾病的药物利用评价标准构建与应用
- Author:
Liang WU
1
;
Wei WANG
2
;
Yanghui XU
1
;
Bo ZHU
1
;
Yijun KE
1
Author Information
1. Dept. of Pharmaceutical Management，Anqing Municipal Hospital，Anhui Anqing 246003，China
2. Dept. of Gastroenterology，Anqing Municipal Hospital，Anhui Anqing 246003，China
- Publication Type:Journal Article
- Keywords:
rivaroxaban;
dual pathway inhibition antithrombotic treatment regimen;
atherosclerotic cardiovascular disease
- From:
China Pharmacy
2025;36(17):2176-2181
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To construct and apply drug utilization evaluation （DUE） criteria for low-dose rivaroxaban in atherosclerotic cardiovascular disease （ASCVD） based on the dual pathway inhibition （DPI） antithrombotic therapy scheme， to promote clinical rational drug use. METHODS Based on the instructions and relevant guidelines of low-dose rivaroxaban （2.5 mg， bid）， the Delphi method was used to establish the DUE criteria for low-dose rivaroxaban used in ASCVD. Weighted technique for order preference by similarity to an ideal solution method was used to determine the relative weights of each evaluation index， and the rationality of the filing medical records of discharged patients using low-dose rivaroxaban for ASCVD at Anqing Municipal Hospital from February 2024 to January 2025 was evaluated. RESULTS The established DUE criteria included 3 primary indicators （medication indications， medication process， medication results） and 11 secondary indicators （such as indications， contraindications， etc.）. The higher weighted secondary indicators being contraindications （0.117 9） and indications （0.112 1）. A total of 265 medical records were included for evaluation. The evaluation results showed that 192 cases （72.45%） had reasonable medical records， 69 cases （26.04%） had basic reasonable medical records， and 4 cases （1.51%） had unreasonable medical records； unreasonable types mainly included inappropriate combination therapy， inappropriate usage and dosage， inappropriate post- medication monitoring， and inappropriate drug switching， etc. CONCLUSIONS This study establishes a DUE criteria for low-dose rivaroxaban in ASCVD based on the DPI antithrombotic treatment regimen， and the evaluation results are intuitive， reliable， and quantifiable. The use of low-dose rivaroxaban in ASCVD patients in our hospital is relatively reasonable， but further management needs to be strengthened.
